. Comparison of Denosumab versus Zoledronic acid on serum bone alkaline phosphatase (BAP), total procollagen type 1 amino-terminal propeptide (TP1NP), bone gamma carboxy-glutamic acid containing proteins (BGP), and β isomer of C-terminal telopeptide of ty
serum bone alkaline phosphatase (BAP), total procollagen type 1 amino-terminal propeptide (TP1NP), bone gamma carboxy-glutamic acid containing proteins (BGP), and β isomer of C-terminal telopeptide of type I collagen (β-CTX)
Abstract
Background/aim: To compare the efficacy of Denosumab (DEN) versus Zoledronic acid (ZOL) in treating patients with osteoporotic vertebral compression fractures (OVCF) after percutaneous kyphoplasty (PKP).
Materials and methods:In this study, 128 OVCF patients who underwent PKP in our hospital from June 2020 to August 2023 were selected and randomized into a DEN group treated with DEN and a ZOL group treated with ZOL. Bone mineral density (BMD), bone metabolism, pain, and lumbar mobility were compared between the two groups before and after treatment, and the anterior vertebral height and local kyphotic angle were measured. Finally, the one-year re-fracture rate and treatment cost were counted.
Results: The two groups showed no notable difference in pain, lumbar mobility, anterior vertebral height, and local kyphotic angle after treatment (P>0.05). BMD was higher in DEN group at 6 and 12 months after treatment, while β isomer of C-terminal telopeptide of type I collagen (β-CTX) was lower (P<0.05). No statistical inter-group difference was identified in the one-year re-fracture rate (P>0.05), while the total treatment cost was lower in DEN group compared with ZOL group (P<0.05). Conclusions: Both DEN and ZOL is effective in improving the prognosis of OVCF patients after PKP, but DEN can more significantly improve BMD and bone metabolism with higher economic benefits.
References
1. Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C (2023) Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med 176 (2): 182-195. doi: 10.7326/M22-0684
2. Wu D, Cline-Smith A, Shashkova E, Perla A, Katyal A, Aurora R (2021) T-Cell Mediated Inflammation in Postmenopausal Osteoporosis. Front Immunol 12: 687551. doi: 10.3389/fimmu.2021.687551
3. Ren C, Gong W, Li F, Xie M (2019) Protective and therapeutic effects of Pilose antler against kidney deficiency-induced osteoporosis. Cell Mol Biol (Noisy-le-grand) 65 (5): 24-31. doi:
4. Arceo-Mendoza RM, Camacho PM (2021) Postmenopausal Osteoporosis: Latest Guidelines. Endocrinol Metab Clin North Am 50 (2): 167-178. doi: 10.1016/j.ecl.2021.03.009
5. Prost S, Pesenti S, Fuentes S, Tropiano P, Blondel B (2021) Treatment of osteoporotic vertebral fractures. Orthop Traumatol Surg Res 107 (1S): 102779. doi: 10.1016/j.otsr.2020.102779
6. Kutsal FY, Ergin Ergani GO (2021) Vertebral compression fractures: Still an unpredictable aspect of osteoporosis. Turk J Med Sci 51 (2): 393-399. doi: 10.3906/sag-2005-315
7. Li J, Xu L, Liu Y, Sun Z, Wang Y, Yu M, Li W, Zeng Y (2023) Open Surgical Treatments of Osteoporotic Vertebral Compression Fractures. Orthop Surg 15 (11): 2743-2748. doi: 10.1111/os.13822
8. Di Lorenzo L (2023) Denosumab in elderly osteoporotic patients. A narrative review. Clin Ter 174 (6): 545-549. doi: 10.7417/CT.2023.5023
9. Tian P, Liu Y, Li ZJ, Xu GJ, Ma XL (2021) Zoledronic Acid in Osteoporotic Vertebral Compression Fractures Treated With Percutaneous Kyphoplasty: A Meta-Analysis. Front Surg 8: 668551. doi: 10.3389/fsurg.2021.668551
10. Ijuin A, Yoshikata H, Asano R, Tsuburai T, Kikuchi R, Sakakibara H (2017) Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: A case study. Taiwan J Obstet Gynecol 56 (6): 863-866. doi: 10.1016/j.tjog.2017.10.028
11. Zhuang M, Cai B, Wang F (2022) Effectiveness and safety of percutaneous kyphoplasty combined with zoledronic acid in treatment of osteoporotic vertebral compression fractures: a meta-analysis. Arch Orthop Trauma Surg 142 (10): 2435-2443. doi: 10.1007/s00402-021-03858-4
12. Sung YT, Wu JS (2018) The Visual Analogue Scale for Rating, Ranking and Paired-Comparison (VAS-RRP): A new technique for psychological measurement. Behav Res Methods 50 (4): 1694-1715. doi: 10.3758/s13428-018-1041-8
13. Tetreault L, Kopjar B, Nouri A, Arnold P, Barbagallo G, Bartels R, Qiang Z, Singh A, Zileli M, Vaccaro A, Fehlings MG (2017) The modified Japanese Orthopaedic Association scale: establishing criteria for mild, moderate and severe impairment in patients with degenerative cervical myelopathy. Eur Spine J 26 (1): 78-84. doi: 10.1007/s00586-016-4660-8
14. Hammed A, Mahfoud M, Mohamad O (2023) Effectiveness of unilateral percutaneous vertebroplasty for acute traumatic non-osteoporotic compression vertebral fractures. Medicine (Baltimore) 102 (37): e35177. doi: 10.1097/MD.0000000000035177
15. Lamanna A, Maingard J, Kok HK, Ranatunga D, Looby ST, Brennan P, Chua M, Owen A, Brooks DM, Chandra RV, Asadi H (2019) Vertebroplasty for acute painful osteoporotic vertebral compression fractures: An update. J Med Imaging Radiat Oncol 63 (6): 779-785. doi: 10.1111/1754-9485.12900
16. Cheng J, Ju S, Zhang Z (2023) Osteoporotic vertebral compression fractures caused by Cushing's syndrome in young women: case report and literature review. BMC Musculoskelet Disord 24 (1): 167. doi: 10.1186/s12891-023-06253-9
17. Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther 39 (1): 58-74. doi: 10.1007/s12325-021-01936-y
18. Xie LL, Yu H, Yuan X, Pu D (2023) A review of the zoledronic acid combined with percutaneous vertebroplasty in the osteoporotic vertebral compression fracture. Asian J Surg 46 (1): 642-644. doi: 10.1016/j.asjsur.2022.07.020
19. Tang B, Zeng H, Hu S, Liu K, Wu L, Shi X (2022) Percutaneous Vertebroplasty Combined with Zoledronic Acid in Treatment and Prevention of Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis of Comparative Studies. World Neurosurg 157: 75-87. doi: 10.1016/j.wneu.2021.09.131
20. Davis S, Simpson E, Hamilton J, James MM, Rawdin A, Wong R, Goka E, Gittoes N, Selby P (2020) Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess 24 (29): 1-314. doi: 10.3310/hta24290
21. Deligiorgi MV, Trafalis DT (2021) The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. Expert Opin Drug Saf 20 (2): 191-213. doi: 10.1080/14740338.2021.1861246
22. Liu K, Tan G, Sun W, Lu Q, Tang J, Yu D (2023) Percutaneous kyphoplasty combined with zoledronic acid for the treatment of primary osteoporotic vertebral compression fracture: a prospective, multicenter study. Arch Orthop Trauma Surg 143 (7): 3699-3706. doi: 10.1007/s00402-022-04557-4
23. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386 (9999): 1147-1155. doi: 10.1016/S0140-6736(15)61120-5
Copyright (c) 2024 Jiayin Meng
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.